Crossing the borders of innovationBasing clinical trials on sound mechanistic and scientific rationale. Combating Pan-Cancer with PrecisionSaving Lives of Patients Who Exhausted Treatment Options and Improving Clinical BenefitsCancer Patients are fighting for their lives...we will fight with themImagining a world without cancer. Apollomics is an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies. Pipeline Science Events Our Vision To become a global leader in the development of novel medicines for cancer patients. Learn More Recent News September 27, 2020 Apollomics, Inc. Receives China Investigational New Drug Approval for APL-106 to Initiate a Phase 3 Bridging Study in Acute Myeloid Leukemia May 21, 2020 Apollomics, Inc. Announces Initiation of SPARTA Phase 2 Clinical Trial for c-MET Inhibitor APL-101 More News
